sotrastaurin + tacrolimus

Sotrastaurin + tacrolimus is a combination of two immunosuppressive drugs used primarily in the context of organ transplantation to prevent acute rejection. Sotrastaurin is a novel small molecule inhibitor of protein kinase C, which blocks early T cell activation and reduces cytokine production such as interleukin-2 and tumor necrosis factor. Tacrolimus is a calcineurin inhibitor that suppresses immune responses by inhibiting T-cell activation through blocking interleukin-2 transcription. The combination has been studied in clinical trials for kidney and liver transplantation, showing potentially enhanced immunosuppressive activity but also pharmacokinetic interactions—sotrastaurin increases tacrolimus exposure, requiring dose adjustments. Both agents are administered under close medical supervision due to risks including infection and malignancy[1][4][5][6].

Brand names

Prograf (tacrolimus)

Other names

sotrastaurin + tacrolimus